XOMA Royalty Corporation
XOMA Royalty Corporation
XOMA
NASDAQ
29.25
USD
27.56%
About
XOMA Royalty Corporation, formerly XOMA Corporation, is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners.
The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab)..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 23.4K |
| Three Month Average Volume | 522.0K |
| High Low | |
| Fifty-Two Week High | 30.36 USD |
| Fifty-Two Week Low | 13.48 USD |
| Fifty-Two Week High Date | 25 Jul 2024 |
| Fifty-Two Week Low Date | 04 Oct 2023 |
| Price and Volume | |
| Current Price | 29.25 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 11.24% |
| Thirteen Week Relative Price Change | 5.97% |
| Twenty-Six Week Relative Price Change | 6.84% |
| Fifty-Two Week Relative Price Change | 66.50% |
| Year-to-Date Relative Price Change | 33.52% |
| Price Change | |
| One Day Price Change | -0.85% |
| Thirteen Week Price Change | 13.42% |
| Twenty-Six Week Price Change | 17.47% |
| Five Day Price Change | 3.54% |
| Fifty-Two Week Price Change | 108.63% |
| Year-to-Date Price Change | 58.11% |
| Month-to-Date Price Change | 9.30% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 7.7179 USD |
| Book Value Per Share (Most Recent Quarter) | 8.57692 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 7.7179 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 8.57692 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.19421 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.41479 USD |
| Revenue Per Share (Trailing Twelve Months) | 1.17433 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -4.03653 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.22491 USD |
| Normalized (Last Fiscal Year) | -2.6567 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -4.03653 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.19068 USD |
| Including Extraordinary Items (Last Fiscal Year) | -4.03653 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.22491 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 13.3488 USD |
| Cash Per Share (Most Recent Quarter) | 12.4031 USD |
| Cash Flow Per Share (Last Fiscal Year) | -3.95807 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.79136 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.05843 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -29 |
| Cash Flow Revenue (Trailing Twelve Months) | -90 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -119.61% |
| Pretax Margin (Last Fiscal Year) | -858.15% |
| Pretax Margin (5 Year) | -33.35% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -879.53% |
| Operating Margin (Trailing Twelve Months) | -154.13% |
| Operating Margin (5 Year) | -34.65% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -858.15% |
| Net Profit Margin (Trailing Twelve Months) | -119.61% |
| Net Profit Margin (5 Year) | -31.87% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 28.99% |
| Tangible Book Value (5 Year) | 36.41% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 568.64% |
| Revenue Growth (3 Year) | -2.13% |
| Revenue Change (Trailing Twelve Months) | 277.95% |
| Revenue Per Share Growth | -8.10% |
| Revenue Growth (5 Year) | -45.50% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 23.16% |
| Total Debt (5 Year) | 40.73% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 242.97% |
| EPS Change (Trailing Twelve Months) | 17.34% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 4 |
| Price to Tangible Book (Most Recent Quarter) | 3 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -23,807,000 |
| Net Debt (Last Fiscal Year) | -29,390,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 72 |
| Price to Sales (Trailing Twelve Months) | 22 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 274 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 51 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 4 |
| Price to Book (Most Recent Quarter) | 3 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 134 |
| Long Term Debt to Equity (Most Recent Quarter) | 115 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 9 |
| Current Ratio (Most Recent Quarter) | 9 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -23,647,000 |
| Free Cash Flow (Trailing Twelve Months) | -13,735,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 140 |
| Total Debt to Equity (Most Recent Quarter) | 121 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -21.79% |
| Return on Assets (Trailing Twelve Months) | -9.88% |
| Return on Assets (5 Year) | -4.55% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -43.55% |
| Return on Equity (Trailing Twelve Months) | -23.90% |
| Return on Equity (5 Year) | -11.98% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -23.44% |
| Return on Investment (Trailing Twelve Months) | -10.62% |
| Return on Investment (5 Year) | -4.94% |